US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Odyssey Therapeutics

24.36

-1.6200-6.24%

Volume:117.28K

Turnover:2.95M

Market Cap:1.17B

PE:-7.29

High:26.52

Open:26.05

Low:24.25

Close:25.98

52wk High:28.00

52wk Low:15.10

Shares:48.03M

Float Shares:13.24M

Volume Ratio:0.60

T/O Rate:0.89%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.3410

EPS(LYR):-50.1297

ROE:-85.50%

ROA:-41.66%

PB:2.78

PE(LYR):-0.49

Loading ...

Overview Company News Filings

Odyssey Therapeutics initiated with an Overweight at JPMorgan

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

TPG Orazio II buys 1,388,889 Odyssey Therapeutics shares for $25 million

Odyssey Therapeutics director Dimension Capital II files initial beneficial ownership statement

Odyssey Therapeutics raises USD 304 million in upsized Nasdaq IPO at USD 18 share price

SR One Capital Management reports Odyssey Therapeutics disposal worth $19,116

Odyssey Therapeutics director Jeffrey M. Leiden buys 5,000 shares for $100,000

Odyssey Therapeutics CFO Jason Haas acquires 1,000 shares worth $20,000

Odyssey Therapeutics director Li Nan acquires common shares worth $20 million

Odyssey Therapeutics Director Shelley Chu acquires $199,998 common shares in IPO

Odyssey Therapeutics issues unregistered shares in private placement under Securities Act exemption

Odyssey Therapeutics Shares Open at $20 in Nasdaq Debut VS $18 IPO Price

THOMSON REUTERS

NASDAQ TRADE HALT IPO SECURITY RELEASED FOR QUOTATION AT 11:06 AM

Odyssey Therapeutics Prices Upsized IPO at $18 Per Share

MT Newswires Live

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

Biotech firm Odyssey raises $279 million in upsized US IPO

BRIEF-Odyssey Therapeutics Announces Pricing Of Upsized Initial Public Offering

Odyssey Therapeutics Inc - Prices Upsized IPO of 15.5 Mln Shares at $18.00 per Share

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ODTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","market":"US","secType":"STK","nameCN":"Odyssey Therapeutics","latestPrice":24.36,"timestamp":1787947200000,"preClose":25.98,"halted":0,"volume":117279,"delay":0,"changeRate":-0.062355658198614355,"floatShares":13240000,"shares":48031300,"eps":-3.341,"marketStatus":"Pre-Mkt","change":-1.62,"latestTime":"08-31 08:42:05 EDT","open":26.05,"high":26.515,"low":24.25,"amount":2951002.34496,"amplitude":0.087182,"askPrice":24.97,"askSize":1,"bidPrice":9.75,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.341,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788183000000},"marketStatusCode":1,"adr":0,"listingDate":1778212800000,"exchange":"NASDAQ","adjPreClose":24.36,"postHourTrading":{"tag":"盘后","latestPrice":24.36,"preClose":24.36,"latestTime":"19:30 EDT","volume":247,"amount":6020.62,"timestamp":1787959806531,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5986591307123087},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","floatShares":13240000,"roa":"-41.66%","roe":"-85.50%","lyrEps":-50.129685,"volumeRatio":0.5986591307123087,"shares":48031300,"dividePrice":0,"high":26.515,"amplitude":0.087182,"preClose":25.98,"low":24.25,"week52Low":15.1,"pbRate":"2.78","psRate":"11818.61","week52High":28,"institutionHeld":0,"latestPrice":24.36,"committee":0.99005,"eps":-3.341,"divideRate":0,"volume":117279,"delay":0,"ttmEps":-3.341,"open":26.05,"prevYearClose":18,"prevWeekClose":24.36,"prevMonthClose":18.93,"prevQuarterClose":18.71,"fiveDayClose":26.39,"twentyDayClose":18.93,"sixtyDayClose":16.69},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"ODTX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODTX","date":"2026-08-28","current":-7.29123,"percent":0.026316,"low":-7.902217,"twenty":-6.206789,"median":-5.687036,"eighty":-5.395703,"high":-5.017591,"avg":-5.903587,"sd":0.662537,"marketCap":1244921564},"quantilePoints":[{"date":"2026-05-08","current":-5.722186,"twenty":-5.722186,"median":-5.722186,"eighty":-5.722186,"marketCap":850585842},{"date":"2026-05-15","current":-5.496622,"twenty":-5.693383,"median":-5.609284,"eighty":-5.496622,"marketCap":817056381},{"date":"2026-05-22","current":-5.629912,"twenty":-5.680689,"median":-5.537878,"eighty":-5.38396,"marketCap":836869527},{"date":"2026-05-29","current":-5.687036,"twenty":-5.681958,"median":-5.553746,"eighty":-5.441085,"marketCap":845360875},{"date":"2026-06-05","current":-5.395068,"twenty":-5.640067,"median":-5.507729,"eighty":-5.381104,"marketCap":801960652},{"date":"2026-06-12","current":-5.33477,"twenty":-5.599446,"median":-5.433151,"eighty":-5.365236,"marketCap":792997562},{"date":"2026-06-18","current":-5.864756,"twenty":-5.646414,"median":-5.455366,"eighty":-5.369045,"marketCap":871778402},{"date":"2026-06-26","current":-5.739918,"twenty":-5.704904,"median":-5.528358,"eighty":-5.374757,"marketCap":852228560},{"date":"2026-07-02","current":-5.356182,"twenty":-5.790223,"median":-5.545812,"eighty":-5.374122,"marketCap":795253729},{"date":"2026-07-10","current":-5.427125,"twenty":-5.732825,"median":-5.496622,"eighty":-5.359042,"marketCap":805786891},{"date":"2026-07-17","current":-5.501292,"twenty":-5.710665,"median":-5.510065,"eighty":-5.36714,"marketCap":816798833},{"date":"2026-07-24","current":-5.697997,"twenty":-5.732825,"median":-5.553746,"eighty":-5.374122,"marketCap":846004419},{"date":"2026-07-31","current":-5.939848,"twenty":-5.856557,"median":-5.572788,"eighty":-5.377217,"marketCap":881912925},{"date":"2026-08-07","current":-6.447481,"twenty":-5.942427,"median":-5.59659,"eighty":-5.382058,"marketCap":1031771093},{"date":"2026-08-14","current":-6.204393,"twenty":-6.026914,"median":-5.668975,"eighty":-5.382691,"marketCap":992870470},{"date":"2026-08-21","current":-7.387181,"twenty":-6.093162,"median":-5.678649,"eighty":-5.386182,"marketCap":1182148383},{"date":"2026-08-28","current":-7.779447,"twenty":-6.206789,"median":-5.687036,"eighty":-5.395703,"marketCap":1244921564}],"updateTime":1788157381030},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640919343","title":"Odyssey Therapeutics initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919343","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640919343?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:05","pubTimestamp":1780391108,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Brian Cheng initiated coverage of Odyssey Therapeutics (ODTX) with an Overweight rating and $26 price target Odyssey is a clinical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/odyssey-therapeutics-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/odyssey-therapeutics-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913560","title":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913560","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640913560?lang=en_us&edition=fundamental","pubTime":"2026-06-02 15:49","pubTimestamp":1780386551,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik June 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Edgewise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL4N42A0K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GGLS","EWTX","SAIL","U","IBM","ORCX","GGLL","GOOX","CPB","BXMT","CAG","FULC","NAVN","GOOY","SAIC","UNX","MLM","TTWO","GOOW","MOBI","GOOP","ODTX","ALGT","GH","VMC","EW","GOU","BRKR","ORCS","MANE","OCTV","TMHC","HPE","CIEN","ARXS","ORCL","CZR","RBRK","PRAX","BTSG","ACRE","CHWY","MAC","LTH","XFOR","GOOGL","BWA","ORCU","RVMD","SOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756078","title":"TPG Orazio II buys 1,388,889 Odyssey Therapeutics shares for $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756078","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756078?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:11","pubTimestamp":1778706689,"startTime":"0","endTime":"0","summary":"TPG GP A reported indirect ownership of 3,690,146 Odyssey Therapeutics common shares following transactions tied to company initial public offering.Position included 1,388,889 shares bought at USD 18 per share.Holdings also reflected 1,880,497 shares received from automatic conversion of Series D Preferred Stock.Report listed TPG GP A as former 10% owner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL8Z9r8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TPG Orazio II buys 1,388,889 Odyssey Therapeutics shares for $25 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635922531","title":"Odyssey Therapeutics director Dimension Capital II files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2635922531","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635922531?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:37","pubTimestamp":1778621838,"startTime":"0","endTime":"0","summary":"Dimension Capital II, a director, reported 512,862 Odyssey Therapeutics common shares in initial beneficial ownership filing dated May 7.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL97fksf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634057214","title":"Odyssey Therapeutics raises USD 304 million in upsized Nasdaq IPO at USD 18 share price","url":"https://stock-news.laohu8.com/highlight/detail?id=2634057214","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634057214?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:11","pubTimestamp":1778591460,"startTime":"0","endTime":"0","summary":"Jeito Capital participated in portfolio company Odyssey Therapeutics’ upsized IPO on Nasdaq, raising USD 304 million at USD 18 per share.Odyssey began trading May 8 under ticker ODTX; offering included 15,500,000 shares in IPO plus 1,388,889 shares sold in concurrent private placement to affiliate of TPG Life Sciences Innovations.Jeito investment followed its participation in Odyssey’s USD 213 million Series D financing in September 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jeito Capital SAS published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLz8Vjd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634254261","title":"SR One Capital Management reports Odyssey Therapeutics disposal worth $19,116","url":"https://stock-news.laohu8.com/highlight/detail?id=2634254261","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634254261?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:12","pubTimestamp":1778548350,"startTime":"0","endTime":"0","summary":"SR One Capital Management, a 10% owner of Odyssey Therapeutics, reported a jump in beneficial ownership tied to its pre-IPO holdings converting into common stock on May 11, 2026.Holdings reported through affiliated funds rose to 1,831,383 shares, 574,314 shares, and 1,014,851 shares following the transactions.Form 4 also showed small net-exercise withholdings for warrant exercises, including 1,065 shares, 277 shares, and 438 shares withheld.SR One Capital Management reported open-market purchases at USD 18, including 222,222 shares, 133,333 shares, and 200,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6rkRjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634251462","title":"Odyssey Therapeutics director Jeffrey M. Leiden buys 5,000 shares for $100,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2634251462","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634251462?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:35","pubTimestamp":1778546154,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics director Jeffrey M. Leiden reported purchase of 5,000 common shares at USD 20, lifting direct holdings to 270,198 shares.Racing Beach Ventures LLC, where Leiden is managing member, reported 31,644 Odyssey common shares held indirectly following preferred-stock conversions and warrant exercise tied to IPO-related restructuring.Leiden also reported receipt of a stock option for 626,220 shares with an exercise price of USD 18.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is sole","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7fbBT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634166251","title":"Odyssey Therapeutics CFO Jason Haas acquires 1,000 shares worth $20,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2634166251","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634166251?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:33","pubTimestamp":1778546005,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics CFO Jason Haas reported purchase of 1,000 common shares at USD 20 per share.Directly held common stock position rose to 62,908 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLjLmk2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634131251","title":"Odyssey Therapeutics director Li Nan acquires common shares worth $20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634131251","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634131251?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:31","pubTimestamp":1778545869,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics director Li Nan reported an increase in indirect holdings to 3,333,516 common shares.Filing showed 1,111,111 shares acquired at USD 18 per share.Report also reflected conversion into 1,709,543 common shares, lifting total indirect ownership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1TKHPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634251133","title":"Odyssey Therapeutics Director Shelley Chu acquires $199,998 common shares in IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2634251133","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634251133?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:31","pubTimestamp":1778545861,"startTime":"0","endTime":"0","summary":"Shelley Chu, director, reported purchase of 11,111 Odyssey Therapeutics common shares.Shares were bought at USD 18 per share.Direct holdings rose to 11,111 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6w3xPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Odyssey Therapeutics Director Shelley Chu acquires $199,998 common shares in IPO","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634223099","title":"Odyssey Therapeutics issues unregistered shares in private placement under Securities Act exemption","url":"https://stock-news.laohu8.com/highlight/detail?id=2634223099","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634223099?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:33","pubTimestamp":1778531639,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics disclosed an unregistered sale of shares in a private placement.Shares were issued under Securities Act exemption Section 4.Purchaser represented it is an institutional accredited investor under Regulation D or a qualified institutional buyer under Rule 144A.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL927F9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633746840","title":"Odyssey Therapeutics Shares Open at $20 in Nasdaq Debut VS $18 IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2633746840","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633746840?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:51","pubTimestamp":1778255498,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L1VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633501094","title":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:06 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633501094","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633501094?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:06","pubTimestamp":1778252811,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  IPO SECURITY RELEASED FOR QUOTATION AT 11:06 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nAQN2LYBKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633678433","title":"Odyssey Therapeutics Prices Upsized IPO at $18 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633678433","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633678433?lang=en_us&edition=fundamental","pubTime":"2026-05-08 16:10","pubTimestamp":1778227858,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics has priced its upsized initial public offering at $18 per share for 15.5 million shares, for gross proceeds of about $304 million, the company said late Thursday.Underwriters have","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPCX","ODTX","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633438010","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633438010","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633438010?lang=en_us&edition=fundamental","pubTime":"2026-05-08 16:00","pubTimestamp":1778227202,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nAQN2LY82V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101112","title":"Biotech firm Odyssey raises $279 million in upsized US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101112","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633101112?lang=en_us&edition=fundamental","pubTime":"2026-05-08 08:51","pubTimestamp":1778201512,"startTime":"0","endTime":"0","summary":"Biotech firm Odyssey raises $279 million in upsized US IPOMay 7  - Biopharmaceutical company Odyssey Therapeutics ODTX.O has raised $279 million in its upsized U.S. initial public offering, the company said on Thursday.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL4N41K10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633210195","title":"BRIEF-Odyssey Therapeutics Announces Pricing Of Upsized Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2633210195","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633210195?lang=en_us&edition=fundamental","pubTime":"2026-05-08 08:46","pubTimestamp":1778201208,"startTime":"0","endTime":"0","summary":"BRIEF-Odyssey Therapeutics Announces Pricing Of Upsized Initial Public OfferingMay 7 (Reuters) - Odyssey Therapeutics Inc ODTX.O:ODYSSEY THERAPEUTICS ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA1Q8WY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101989","title":"Odyssey Therapeutics Inc - Prices Upsized IPO of 15.5 Mln Shares at $18.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633101989?lang=en_us&edition=fundamental","pubTime":"2026-05-08 08:45","pubTimestamp":1778201119,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA1Q8WY3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}